{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:32:18Z","timestamp":1792801938071,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":60,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"research grants from the Japan Society for the Promotion of Science, Tokyo, Japan","award":["Nos. 24K10621 and 21K07416)"],"award-info":[{"award-number":["Nos. 24K10621 and 21K07416)"]}],"id":[{"id":"https:\/\/ror.org\/00hhkn466","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Astellas Pharma Inc","id":[{"id":"https:\/\/ror.org\/01cjash87","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Grants for research on intractable diseases (Neuroimmunological Disease Research Committee) from the Ministry of Health, Labour and Welfare of Japan","id":[{"id":"https:\/\/ror.org\/03mwa7s65","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Chugai Foundation for Innovation Drug Discovery Science and Life Science Foundation of JAPAN","id":[{"id":"https:\/\/ror.org\/05q5mgf13","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012131","name":"Brain Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012131","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Takeda science fundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"DOI":"10.1186\/s40478-026-02307-w","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:32:28Z","timestamp":1777890748000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["TRIM21 autoantibodies are associated with blood-brain barrier dysfunction in a subgroup of neuromyelitis optica spectrum disorder"],"prefix":"10.1186","volume":"14","author":[{"given":"Fumitaka","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Kadono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Yuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotada","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Mizukami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanami","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Nakamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"issue":"2","key":"2307_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/jnnp-2016-313300","volume":"88","author":"I Kawachi","year":"2017","unstructured":"Kawachi I, Lassmann H (2017) Neurodegeneration in multiple sclerosis and euromyelitis optica. J Neurol Neurosurg Psychiatry 88(2):137\u2013145. https:\/\/doi.org\/10.1136\/jnnp-2016-313300","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"2307_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202(4):473\u2013477. https:\/\/doi.org\/10.1084\/jem.20050304","journal-title":"J Exp Med"},{"issue":"2","key":"2307_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM de Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177\u2013189. https:\/\/doi.org\/10.1212\/WNL.0000000000001729","journal-title":"Neurology"},{"issue":"1","key":"2307_CR4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","volume":"18","author":"E Carnero Contentti","year":"2021","unstructured":"Carnero Contentti E, Correale J (2021) Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. J Neuroinflammation 18(1):208. https:\/\/doi.org\/10.1186\/s12974-021-02249-1","journal-title":"J Neuroinflammation"},{"key":"2307_CR5","doi-asserted-by":"publisher","first-page":"117957352412310","DOI":"10.1177\/11795735241231094","volume":"16","author":"M Anderson","year":"2024","unstructured":"Anderson M, Levy M (2024) Advances in the long-term treatment of neuromyelitis optica spectrum disorder. J Cent Nerv Syst Dis 16:11795735241231094. https:\/\/doi.org\/10.1177\/11795735241231094","journal-title":"J Cent Nerv Syst Dis"},{"issue":"9","key":"2307_CR6","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1073\/pnas.1017385108","volume":"108","author":"N Chihara","year":"2011","unstructured":"Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S, Okamoto T, Ogawa M, Toda T, Yamamura T (2011) Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 108(9):3701\u20133706. https:\/\/doi.org\/10.1073\/pnas.1017385108","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2307_CR7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","volume":"11","author":"MC Papadopoulos","year":"2012","unstructured":"Papadopoulos MC, Verkman AS (2012) Aquaporin 4 and neuromyelitis optica. Lancet Neurol 11(6):535\u2013544. https:\/\/doi.org\/10.1016\/S1474-4422(12)70133-3","journal-title":"Lancet Neurol"},{"issue":"5","key":"2307_CR8","doi-asserted-by":"publisher","first-page":"e841","DOI":"10.1212\/NXI.0000000000000841","volume":"7","author":"K Fujihara","year":"2020","unstructured":"Fujihara K, Bennett JL, de Seze J, Haramura M, Kleiter I, Weinshenker BG, Kang D, Mughal T, Yamamura T (2020) Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm 7(5):e841. https:\/\/doi.org\/10.1212\/NXI.0000000000000841","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"2307_CR9","doi-asserted-by":"publisher","first-page":"e311","DOI":"10.1212\/NXI.0000000000000311","volume":"4","author":"Y Takeshita","year":"2016","unstructured":"Takeshita Y, Obermeier B, Cotleur AC, Spampinato SF, Shimizu F, Yamamoto E, Sano Y, Kryzer TJ, Lennon VA, Kanda T, Ransohoff RM (2016) Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm 4(1):e311. https:\/\/doi.org\/10.1212\/NXI.0000000000000311","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"2307_CR10","doi-asserted-by":"publisher","first-page":"e1076","DOI":"10.1212\/NXI.0000000000001076","volume":"8","author":"Y Takeshita","year":"2021","unstructured":"Takeshita Y, Fujikawa S, Serizawa K, Fujisawa M, Matsuo K, Nemoto J, Shimizu F, Sano Y, Tomizawa-Shinohara H, Miyake S, Ransohoff RM, Kanda T (2021) New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD. Neurol Neuroimmunol Neuroinflamm 8(6):e1076. https:\/\/doi.org\/10.1212\/NXI.0000000000001076","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"19","key":"2307_CR11","doi-asserted-by":"publisher","first-page":"10625","DOI":"10.3390\/ijms251910625","volume":"25","author":"F Shimizu","year":"2024","unstructured":"Shimizu F, Nakamori M (2024) Blood-brain barrier disruption in neuroimmunological disease. Int J Mol Sci 25(19):10625. https:\/\/doi.org\/10.3390\/ijms251910625","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2307_CR12","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1080\/25785826.2018.1531190","volume":"41","author":"F Shimizu","year":"2018","unstructured":"Shimizu F, Nishihara H, Kanda T (2018) Blood-brain barrier dysfunction in immuno-mediated neurological diseases. Immunol Med 41(3):120\u2013128. https:\/\/doi.org\/10.1080\/25785826.2018.1531190","journal-title":"Immunol Med"},{"issue":"4","key":"2307_CR13","doi-asserted-by":"publisher","first-page":"e727","DOI":"10.1212\/NXI.0000000000000727","volume":"7","author":"J Jitprapaikulsan","year":"2020","unstructured":"Jitprapaikulsan J, Fryer JP, Majed M, Smith CY, Jenkins SM, Cabre P, Hinson SR, Weinshenker BG, Mandrekar J, Chen JJ, Lucchinetti CF, Jiao Y, Segan J, Schmeling JE, Mills J, Flanagan EP, McKeon A, Pittock SJ (2020) Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD. Neurol Neuroimmunol Neuroinflamm 7(4):e727. https:\/\/doi.org\/10.1212\/NXI.0000000000000727","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"2307_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00401-010-0704-z","volume":"120","author":"R Sharma","year":"2010","unstructured":"Sharma R, Fischer MT, Bauer J, Felts PA, Smith KJ, Misu T, Fujihara K, Bradl M, Lassmann H (2010) Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination. Acta Neuropathol 120(2):223\u2013236. https:\/\/doi.org\/10.1007\/s00401-010-0704-z","journal-title":"Acta Neuropathol"},{"issue":"397","key":"2307_CR15","doi-asserted-by":"publisher","first-page":"eaai9111","DOI":"10.1126\/scitranslmed.aai9111","volume":"9","author":"F Shimizu","year":"2017","unstructured":"Shimizu F, Schaller KL, Owens GP, Cotleur AC, Kellner D, Takeshita Y, Obermeier B, Kryzer TJ, Sano Y, Kanda T, Lennon VA, Ransohoff RM, Bennett JL (2017) Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica. Sci Transl Med 9(397):eaai9111. https:\/\/doi.org\/10.1126\/scitranslmed.aai9111","journal-title":"Sci Transl Med"},{"issue":"10","key":"2307_CR16","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1002\/acn3.50905","volume":"6","author":"F Shimizu","year":"2019","unstructured":"Shimizu F, Takeshita Y, Hamamoto Y, Nishihara H, Sano Y, Honda M, Sato R, Maeda T, Takahashi T, Fujikawa S, Kanda T (2019) GRP 78 antibodies are associated with clinical phenotype in neuromyelitis optica. Ann Clin Transl Neurol 6(10):2079\u20132087. https:\/\/doi.org\/10.1002\/acn3.50905","journal-title":"Ann Clin Transl Neurol"},{"issue":"11","key":"2307_CR17","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.2169\/internalmedicine.9783-22","volume":"62","author":"S Minomo","year":"2023","unstructured":"Minomo S, Ichijo M, Shimizu F, Sato R, Kanda T, Takai Y, Misu T, Sakurai Y, Amino T, Kamata T (2023) Paraneoplastic neuromyelitis optica spectrum disorder related to glucose-regulated protein 78 (GRP78) autoantibodies in a patient with lynch syndrome-associated colorectal cancer. Intern Med 62(11):1653\u20131657. https:\/\/doi.org\/10.2169\/internalmedicine.9783-22","journal-title":"Intern Med"},{"key":"2307_CR18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/jcp.22232","volume":"225","author":"Y Sano","year":"2010","unstructured":"Sano Y, Shimizu F, Abe M et al (2010) Establishment of a new conditionally immortalized human brain microvascular endothelial cell line retaining an in vivo blood-brain barrier function. J Cell Physiol 225:519\u2013528","journal-title":"J Cell Physiol"},{"issue":"8","key":"2307_CR19","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1093\/brain\/awz168","volume":"142","author":"F Shimizu","year":"2019","unstructured":"Shimizu F, Takeshita Y, Sano Y, Hamamoto Y, Shiraishi H, Sato T, Yoshimura S, Maeda T, Fujikawa S, Nishihara H, Kitanosono H, Tsujino A, Motomura M, Kanda T (2019) GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome. Brain 142(8):2253\u20132264","journal-title":"Brain"},{"key":"2307_CR20","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/s42003-020-01443-w","volume":"3","author":"M Kohno","year":"2020","unstructured":"Kohno M, Kobayashi S, Yamamoto T et al (2020) Enhancing calmodulin binding to cardiac ryanodine receptor completely inhibits pressure-overload induced hypertrophic signaling. Commun Biol 3:714","journal-title":"Commun Biol"},{"key":"2307_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12987-018-0108-3","volume":"15","author":"NR Wevers","year":"2018","unstructured":"Wevers NR, Kasi DG, Gray T, Wilschut KJ, Smith B, van Vught R, Shimizu F, Sano Y, Kanda T, Marsh G, Trietsch SJ, Vulto P, Lanz HL, Obermeier B (2018) A perfused human blood-brain barrier on-a-chip for high-throughput assessment of barrier function and antibody transport. Fluids Barriers CNS 15:23","journal-title":"Fluids Barriers CNS"},{"issue":"12","key":"2307_CR22","doi-asserted-by":"publisher","first-page":"6496","DOI":"10.3390\/ijms25126496","volume":"25","author":"M Ohbuchi","year":"2024","unstructured":"Ohbuchi M, Shibuta M, Tetsuka K, Sasaki-Iwaoka H, Oishi M, Shimizu F, Nagasaka Y (2024) Modeling of blood-brain barrier (BBB) dysfunction and immune cell migration using human BBB-on-a-chip for drug discovery research. Int J Mol Sci 25(12):6496","journal-title":"Int J Mol Sci"},{"key":"2307_CR23","doi-asserted-by":"publisher","first-page":"103494","DOI":"10.1016\/j.msard.2022.103494","volume":"58","author":"L Lin","year":"2022","unstructured":"Lin L, Hang H, Zhang J, Lu J, Chen D, Shi J (2022) Clinical significance of anti-SSA\/Ro antibody in Neuromyelitis optica spectrum disorders. Mult Scler Relat Disord 58:103494","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"2307_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s13760-019-01176-6","volume":"120","author":"T Gkaniatsou","year":"2020","unstructured":"Gkaniatsou T, Papadopoulou A, Paul F, Brandt AU, Oertel FC (2020) Frequency of autoimmune disorders and autoantibodies in European patients with neuromyelitis optica spectrum disorders. Acta Neurol Belg 120(1):223\u2013225. https:\/\/doi.org\/10.1007\/s13760-019-01176-6","journal-title":"Acta Neurol Belg"},{"key":"2307_CR25","doi-asserted-by":"publisher","first-page":"103494","DOI":"10.1016\/j.msard.2022.103494","volume":"58","author":"L Lin","year":"2022","unstructured":"Lin L, Hang H, Zhang J, Lu J, Chen D, Shi J (2022) Clinical significance of anti-SSA\/Ro antibody in Neuromyelitis optica spectrum disorders. Mult Scler Relat Disord 58:103494. https:\/\/doi.org\/10.1016\/j.msard.2022.103494","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"2307_CR26","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1007\/s00415-020-10377-6","volume":"268","author":"T Akaishi","year":"2021","unstructured":"Akaishi T, Takahashi T, Fujihara K, Misu T, Fujimori J, Takai Y, Nishiyama S, Abe M, Ishii T, Aoki M, Nakashima I (2021) Impact of comorbid Sj\u00f6gren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. J Neurol 268(5):1938\u20131944. https:\/\/doi.org\/10.1007\/s00415-020-10377-6","journal-title":"J Neurol"},{"issue":"6","key":"2307_CR27","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1177\/1352458511431727","volume":"18","author":"R Estiasari","year":"2012","unstructured":"Estiasari R, Matsushita T, Masaki K, Akiyama T, Yonekawa T, Isobe N, Kira J (2012) Comparison of clinical, immunological and neuroimaging features between anti-aquaporin-4 antibody-positive and antibody-negative Sjogren\u2019s syndrome patients with central nervous system manifestations. Mult Scler 18(6):807\u2013816. https:\/\/doi.org\/10.1177\/1352458511431727","journal-title":"Mult Scler"},{"issue":"11","key":"2307_CR28","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1007\/s10067-022-06299-5","volume":"41","author":"AYS Lee","year":"2022","unstructured":"Lee AYS, Lin MW, Reed JH (2022) Anti-Ro52\/TRIM21 serological subsets identify differential clinical and laboratory parameters. Clin Rheumatol 41(11):3495\u20133501. https:\/\/doi.org\/10.1007\/s10067-022-06299-5","journal-title":"Clin Rheumatol"},{"issue":"9","key":"2307_CR29","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/acr.24597","volume":"74","author":"B Arma\u011fan","year":"2022","unstructured":"Arma\u011fan B, Robinson SA, Bazoberry A, Perin J, Grader-Beck T, Akpek EK, Kim J, Baer AN (2022) Antibodies to both Ro52 and Ro60 for identifying Sj\u00f6gren\u2019s syndrome patients best suited for clinical trials of disease-modifying therapies. Arthritis Care Res (Hoboken) 74(9):1559\u20131565. https:\/\/doi.org\/10.1002\/acr.24597","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2307_CR30","doi-asserted-by":"publisher","first-page":"1115548","DOI":"10.3389\/fimmu.2023.1115548","volume":"14","author":"AYS Lee","year":"2023","unstructured":"Lee AYS, Putty T, Lin MW, Swaminathan S, Suan D, Chataway T, Thurlings RM, Gordon TP, Wang JJ, Reed JH (2023) Isolated anti-Ro52 identifies a severe subset of Sj\u00f6gren\u2019s syndrome patients. Front Immunol 14:1115548. https:\/\/doi.org\/10.3389\/fimmu.2023.1115548","journal-title":"Front Immunol"},{"issue":"1","key":"2307_CR31","first-page":"55","volume":"159","author":"LM Amezcua-Guerra","year":"2023","unstructured":"Amezcua-Guerra LM, Perez-Garcia LF, Jimenez-Rojas V, Marquez-Velasco R, Silveira LH (2023) Anti-Ro52\/TRIM21 antibodies are associated with aberrant inflammatory circuits in patients with systemic autoimmune rheumatic diseases. Gac Med Mex 159(1):55\u201364","journal-title":"Gac Med Mex"},{"issue":"4","key":"2307_CR32","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/labinvest.2011.190","volume":"92","author":"S Lisi","year":"2012","unstructured":"Lisi S, Sisto M, Lofrumento DD, D\u2019Amore M (2012) Sj\u00f6gren\u2019s syndrome autoantibodies provoke changes in gene expression profiles of inflammatory cytokines triggering a pathway involving TACE\/NF-\u03baB. Lab Invest 92(4):615\u2013624. https:\/\/doi.org\/10.1038\/labinvest.2011.190","journal-title":"Lab Invest"},{"issue":"1","key":"2307_CR33","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s12935-023-03143-x","volume":"23","author":"CH Hsu","year":"2023","unstructured":"Hsu CH, Yu YL (2023) The interconnected roles of TRIM21\/Ro52 in systemic lupus erythematosus, primary Sj\u00f6gren\u2019s syndrome, cancers, and cancer metabolism. Cancer Cell Int 23(1):289. https:\/\/doi.org\/10.1186\/s12935-023-03143-x","journal-title":"Cancer Cell Int"},{"key":"2307_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.semcdb.2021.11.005","volume":"126","author":"L Kiss","year":"2022","unstructured":"Kiss L, James LC (2022) The molecular mechanisms that drive intracellular neutralization by the antibody-receptor and RING E3 ligase TRIM21. Semin Cell Dev Biol 126:99\u2013107. https:\/\/doi.org\/10.1016\/j.semcdb.2021.11.005","journal-title":"Semin Cell Dev Biol"},{"issue":"12","key":"2307_CR35","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.it.2017.07.005","volume":"38","author":"DA Rhodes","year":"2017","unstructured":"Rhodes DA, Isenberg DA (2017) TRIM21 and the function of antibodies inside cells. Trends Immunol 38(12):916\u2013926. https:\/\/doi.org\/10.1016\/j.it.2017.07.005","journal-title":"Trends Immunol"},{"issue":"4","key":"2307_CR36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/ni.2548","volume":"14","author":"WA McEwan","year":"2013","unstructured":"McEwan WA, Tam JC, Watkinson RE, Bidgood SR, Mallery DL, James LC (2013) Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat Immunol 14(4):327\u2013336. https:\/\/doi.org\/10.1038\/ni.2548","journal-title":"Nat Immunol"},{"key":"2307_CR37","doi-asserted-by":"publisher","first-page":"1637451","DOI":"10.3389\/fcell.2025.1637451","volume":"13","author":"A Li","year":"2025","unstructured":"Li A, Wang J, Qu Y (2025) TRIM21: a multifaceted regulator in cancer. Front Cell Dev Biol 13:1637451. https:\/\/doi.org\/10.3389\/fcell.2025.1637451","journal-title":"Front Cell Dev Biol"},{"key":"2307_CR38","doi-asserted-by":"publisher","first-page":"104212","DOI":"10.1016\/j.msard.2022.104212","volume":"68","author":"N Apiraksattayakul","year":"2022","unstructured":"Apiraksattayakul N, Songwisit S, Owattanapanich W, Tisavipat N, Siritho S, Prayoonwiwat N, Rattanathamsakul N, Jitprapaikulsan J (2022) AQP4-IgG-positive neuromyelitis optica spectrum disorder and temporally detected neoplasms: case report and systematic review. Mult Scler Relat Disord 68:104212. https:\/\/doi.org\/10.1016\/j.msard.2022.104212","journal-title":"Mult Scler Relat Disord"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-026-02307-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-026-02307-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-026-02307-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T16:09:07Z","timestamp":1783094947000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40478-026-02307-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2307"],"URL":"https:\/\/doi.org\/10.1186\/s40478-026-02307-w","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committees of Yamaguchi Universities. Patient consent obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not commissioned; externally peer reviewed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Provenance and peer review"}}],"article-number":"141"}}